Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Dr Steve Gray @ MRF's Meningitis and Septicaemia 2019


Published on

Epidemiology and surveillance of meningococcal disease in England

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Dr Steve Gray @ MRF's Meningitis and Septicaemia 2019

  1. 1. Epidemiology and surveillance of meningococcal disease in England 1Gray SJ, 2Campbell H, 1Walker AM, 1Patel S, 1Willerton L, 1Lekshmi A, 1Clark S, 1Bai X, 2Ribeiro S, 2Parikh S, 1Guiver M, 1Lucidarme J, 2Ladhani S, 2Ramsay M and 1Borrow R. 1Public Health England (PHE) Meningococcal Reference Unit (MRU), Manchester Royal Infirmary, Manchester, UK. 2 Immunisation and Countermeasures, National Infection Service, PHE, Colindale, London, UK.
  2. 2. Surveillance of IMD in England • Mature surveillance system – since 1984 • Co-operation: ref lab, epidemiologists and immunisation colleagues • Support from all UK microbiology labs and PHE HPTs – actively encourage submissions • Lab confirmation of IMD in UK underpins the best surveillance  Comprehensive cleaned dataset, ability to further characterise cultures (eg MATS / MEASURE)  WGS for IMD cultures from July 2010 (initially funded by MRF) 2
  3. 3. Fig 1: Distribution of IMD cases by diagnostic method, England 3 ~50 ~40% cases PCR+ only MRU request all available cultures Since Oct 1996, free non-culture (PCR) case confirmation – improved epidemiology 754 525 2573
  4. 4. Fig 2: IMD by capsular group and epidemiological year, England 4 • Rapid reduction in C since Nov 1999, monitored very closely • B predominant but steadily, naturally decreasing • Increase in W since 2009, predominant strain cc11 (WGS)
  5. 5. Fig 4: Distribution of confirmed cases of IMD by age and capsular group, England 5 Group B highest in <5 years but since 2015/2016 Group W highest in 65+ years Group W in 15 - 24 years since 2015/2016
  6. 6. Essential continued surveillance 6 Case confirmation Cluster identification / management To detect changes in meningococcal population capsule groups, strains, antibiotic susceptibilities Review clinical presentations To support vaccine design & development - coverage To determine vaccine effectiveness To monitor / modify immunisation schedules